V. Karanikas

发表

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade

C. Klein, T. Schumacher, K. Mertz, 2018, Nature Medicine.

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume II—practical challenges

Daniel K. Wells, V. Thorsson, J. Kirkwood, 2020, Journal for ImmunoTherapy of Cancer.

Society for Immunotherapy of Cancer clinical and biomarkers data sharing resource document: Volume I—conceptual challenges

Daniel K. Wells, V. Thorsson, J. Kirkwood, 2020, Journal for ImmunoTherapy of Cancer.

Flow cytometric measurement of intracellular cytokines detects immune responses in MUC1 immunotherapy.

V. Maino, V. Karanikas, J. Lodding, 2000, Clinical cancer research : an official journal of the American Association for Cancer Research.

A point mutation in the alpha-actinin-4 gene generates an antigenic peptide recognized by autologous cytolytic T lymphocytes on a human lung carcinoma.

P. Coulie, F. Mami-Chouaib, S. Chouaib, 2001, Cancer research.

Foxp3 expression in human cancer cells

K. Gourgoulianis, V. Karanikas, M. Speletas, 2008, Journal of Translational Medicine.

Anti-survivin antibody responses in lung cancer.

K. Gourgoulianis, V. Karanikas, A. Germenis, 2009, Cancer letters.

Fibroblast activation protein-targeted-4-1BB ligand agonist amplifies effector functions of intratumoral T cells in human cancer

C. Klein, K. Mertz, R. Rosenberg, 2020, Journal for ImmunoTherapy of Cancer.

Dendritic cells dictate responses to PD-L1 blockade cancer immunotherapy

C. Klein, P. Hegde, S. Colombetti, 2020, Science Translational Medicine.

Cord blood as a source of non-senescent lymphocytes for tumor immunotherapy.

V. Karanikas, A. Germenis, 2010, Journal of reproductive immunology.

Induction of HLA-A2-restricted CTLs to the mucin 1 human breast cancer antigen.

V. Apostolopoulos, V. Karanikas, J. Haurum, 1997, Journal of immunology.

The immune response of mice and cynomolgus monkeys to macaque mucin 1-mannan.

G. Pietersz, M. Sandrin, V. Karanikas, 2000, Vaccine.

Affinity of Antibodies to MUC1 Antigens

G. Pietersz, V. Karanikas, I. Mckenzie, 1997, Tumor Biology.

Induction of humoral and cellular responses in cynomolgus monkeys immunised with mannan-human MUC1 conjugates.

G. Pietersz, L. Hwang, V. Karanikas, 1999, Vaccine.

Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection

G. Pietersz, V. Karanikas, I. Mckenzie, 2001, Journal of immunotherapy.

Naturally occurring tumor‐specific CD8+ T‐cell precursors in individuals with and without cancer

K. Gourgoulianis, V. Karanikas, A. Germenis, 2010, Immunology and cell biology.

Tumor specific CD8+ T cells in patients with lung cancer and healthy individuals.

V. Karanikas, A. Germenis, 2009, Journal of B.U.ON. : official journal of the Balkan Union of Oncology.

Monoclonal Anti-MAGE-3 CTL Responses in Melanoma Patients Displaying Tumor Regression after Vaccination with a Recombinant Canarypox Virus 1

M. Demoitié, P. Coulie, B. Dréno, 2003, The Journal of Immunology.

Recombinant Canarypox Virus Regression after Vaccination with a Melanoma Patients Displaying Tumor Monoclonal Anti-MAGE-3 CTL Responses in Boon and

M. Demoitié, P. Coulie, B. Dréno, 2003 .

Mannan-MUC1–Pulsed Dendritic Cell Immunotherapy: A Phase I Trial in Patients with Adenocarcinoma

V. Apostolopoulos, G. Pietersz, B. Loveland, 2006, Clinical Cancer Research.

Mannan-MUC 1 ^ Pulsed Dendritic Cell Immunotherapy : APhase I Trial in Patientswith Adenocarcinoma

G. Pietersz, B. Loveland, H. Gan, 2006 .

Indoleamine 2,3-dioxygenase (IDO) expression in lung cancer

K. Gourgoulianis, V. Karanikas, A. Germenis, 2007, Cancer biology & therapy.

Cytolytic T-cell responses of cancer patients vaccinated with a MAGE antigen.

P. Coulie, T. Connerotte, T. Boon, 2002, Immunological reviews.

Polyclonal CTL Responses Observed in Melanoma Patients Vaccinated with Dendritic Cells Pulsed with a MAGE-3.A1 Peptide 1

P. Coulie, G. Schuler, T. Boon, 2003, The Journal of Immunology.

CTL responses of melanoma patients vaccinated with a MAGE antigen

P. Coulie, T. Boon, V. Karanikas, 2003 .

Peptide Dendritic Cells Pulsed with a MAGE-3 . A 1 Melanoma Patients Vaccinated with Polyclonal CTL Responses Observed in

P. Coulie, G. Schuler, T. Boon, 2003 .

Co-expression patterns of tumor-associated antigen genes by non-small cell lung carcinomas: Implications for immunotherapy

K. Gourgoulianis, K. Boukas, V. Karanikas, 2008, Cancer biology & therapy.

Survivin isoform expression patterns in CML patients correlate with resistance to imatinib and progression, but do not trigger cytolytic responses.

E. Gramoustianou, V. Karanikas, K. Ritis, 2011, Clinical immunology.

Exposure and Tumor Fn14 Expression as Determinants of Pharmacodynamics of the Anti-TWEAK Monoclonal Antibody RG7212 in Patients with Fn14-Positive Solid Tumors

J. Schellens, L. Siu, A. Hansen, 2015, Clinical Cancer Research.

A Phase I Monotherapy Study of RG7212, a First-in-Class Monoclonal Antibody Targeting TWEAK Signaling in Patients with Advanced Cancers

J. Schellens, A. Hansen, M. Demario, 2014, Clinical Cancer Research.

Phase Ia and Ib studies of the novel carcinoembryonic antigen (CEA) T-cell bispecific (CEA CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients with metastatic colorectal cancer (mCRC).

J. Albanell, J. Tabernero, H. Hurwitz, 2017 .

ResearchCytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects

K. Gourgoulianis, K. Theodorou, I. Tsougos, 2015 .

Cytolytic T-cell response against Epstein-Barr virus in lung cancer patients and healthy subjects

K. Gourgoulianis, K. Theodorou, I. Tsougos, 2010, Journal of experimental & clinical cancer research : CR.

A Novel Carcinoembryonic Antigen T-Cell Bispecific Antibody (CEA TCB) for the Treatment of Solid Tumors

C. Klein, W. Bodmer, M. Bacac, 2016, Clinical Cancer Research.

Determinants of cancer immunotherapy success

V. Karanikas, A. Germenis, 2010, Expert review of vaccines.

403PPhase I studies of the novel carcinoembryonic antigen T-cell bispecific (CEA-CD3 TCB) antibody as a single agent and in combination with atezolizumab: Preliminary efficacy and safety in patients (pts) with metastatic colorectal cancer (mCRC)

J. Albanell, J. Tabernero, H. Hurwitz, 2017 .

Traumatic Brain Injury and Inflammation: Emerging Role of Innate and Adaptive Immunity

K. Fountas, E. Dardiotis, G. Hadjigeorgiou, 2012 .

2 Traumatic Brain Injury and Inflammation : Emerging Role of Innate and Adaptive Immunity

K. Fountas, E. Dardiotis, G. Hadjigeorgiou, 2012 .

Tumor immune escape mediated by indoleamine 2,3-dioxygenase.

V. Karanikas, A. Germenis, M. Zamanakou, 2007, Immunology letters.

Antibody and T cell responses of patients with adenocarcinoma immunized with mannan-MUC1 fusion protein.

V. Apostolopoulos, G. Pietersz, L. Hwang, 1997, The Journal of clinical investigation.

Three-dimensional colon cancer organoids model the response to CEA-CD3 T-cell engagers

C. Klein, I. Melero, M. Bacac, 2022, Theranostics.

Biomarker Technologies to Support Early Clinical Immuno-oncology Development: Advances and Interpretation

Allyson L. Byrd, B. Reis, M. Cannarile, 2021, Clinical Cancer Research.

Hepatic portal infiltrates in mice immunized with syngeneic lymphoid cells: Connotations for models of autoimmune liver disease

M. Rowley, I. Mackay, B. Loveland, 1995, Journal of gastroenterology and hepatology.

Foxp3 Expression in Liver Correlates with the Degree but Not the Cause of Inflammation

V. Karanikas, G. Germanidis, K. Ritis, 2011, Mediators of inflammation.

The Where, the When, and the How of Immune Monitoring for Cancer Immunotherapies in the Era of Checkpoint Inhibition

P. Hegde, S. Evers, V. Karanikas, 2016, Clinical Cancer Research.

Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy

L. Miller, J. Kirkwood, J. Galon, 2017, Journal of Immunotherapy for Cancer.

Immunotherapy biomarkers 2016: overcoming the barriers

J. Berzofsky, B. Seliger, B. Fox, 2017, Journal of Immunotherapy for Cancer.

Expression of inhibitory receptors on intratumoral T cells modulates the activity of a T cell-bispecific antibody targeting folate receptor

C. Klein, M. Bacac, P. Pisa, 2016, Oncoimmunology.

A phase 2, single-arm study of an autologous dendritic cell treatment against mucin 1 in patients with advanced epithelial ovarian cancer

M. Quinn, G. Pietersz, B. Loveland, 2014, Journal of Immunotherapy for Cancer.

Baseline levels of CD8+ T cells against survivin and survivin-2B in the blood of lung cancer patients and cancer-free individuals.

K. Gourgoulianis, V. Karanikas, A. Germenis, 2008, Clinical immunology.

Dominant TCR Vα usage by virus and tumor‐reactive T cells with wide affinity ranges for their specific antigens

M. Bonneville, L. Trautmann, P. Coulie, 2002, European journal of immunology.

Progression of Lung Cancer Is Associated with Increased Dysfunction of T Cells Defined by Coexpression of Multiple Inhibitory Receptors

Jens Schreiner, Anton Belousov, Didier Lardinois, 2015, Cancer Immunology Research.

A monoclonal cytolytic T-lymphocyte response observed in a melanoma patient vaccinated with a tumor-specific antigenic peptide encoded by gene MAGE-3

P. Coulie, T. Boon, V. Karanikas, 2001, Proceedings of the National Academy of Sciences of the United States of America.

Cytolytic T‐cell responses of cancer patients vaccinated with a MAGE antigen

P. Coulie, T. Connerotte, T. Boon, 2002 .

Immunoepigenetics: the unseen side of cancer immunoediting

V. Karanikas, A. Germenis, 2007, Immunology and cell biology.

High frequency of cytolytic T lymphocytes directed against a tumor-specific mutated antigen detectable with HLA tetramers in the blood of a lung carcinoma patient with long survival.

E. Schaftingen, P. Coulie, R. Chiari, 2001, Cancer research.

A transcriptionally and functionally distinct PD-1+ CD8+ T cell pool with predictive potential in non-small cell lung cancer treated with PD-1 blockade

C. Klein, T. Schumacher, K. Mertz, 2018, Nature Network Boston.

Novel carcinoembryonic antigen T-cell bispecific (CEA-TCB) antibody: Preliminary clinical data as a single agent and in combination with atezolizumab in patients with metastatic colorectal cancer (mCRC).

J. Albanell, J. Tabernero, H. Hurwitz, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Mannan Mucin-1 Peptide Immunization: Influence of Cyclophosphamide and the Route of Injection.

G. Pietersz, V. Karanikas, G. Thynne, 2001, Journal of immunotherapy : official journal of the Society for Biological Therapy.

CD25 targeting with the afucosylated human IgG1 antibody RG6292 eliminates regulatory T cells and CD25+ blasts in acute myeloid leukemia

C. Klein, K. Korfi, V. Karanikas, 2023, Frontiers in Oncology.